Studies on the efficacy of pyrotinib in the treatment of HER-2 positive advanced solid tumors.

被引：0
|
作者：
Fan, Shaoshuang
Jiang, Da
Lv, Yalei
Cui, Yanzhi
Kong, Yan
Dong, Qian
Huang, Fang
Zhang, Xue
Wang, Long
Zhou, Xinliang
Jin, Hui
Li, Ying
Hou, Ran
机构：
[1] Hebei Med Univ, Hosp 4, Shijiazhuang, Hebei, Peoples R China
[2] Hebei Med Univ, Hosp 4, Dept Med Oncol, Shijiazhuang, Hebei, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e15639
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Retrospective study on the safety and efficacy of pyrotinib in the treatment of HER2positive non-breast advanced solid tumors.
    Wang, Jianzheng
    Zhang, Baiwen
    Cheng, Xiaojiao
    Li, Qingli
    Lv, Huifang
    Nie, Caiyun
    Chen, Beibei
    Xu, Weifeng
    Zhao, Jing
    He, Yunduan
    Tu, Shuiping
    Chen, Xiaobing
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [2] Studies on the Safety and Efficacy of Pyrotinib in the Treatment of HER2-Positive Advanced Solid Tumors Excluding Breast Cancer
    Yin, Yuzhen
    Yang, Hui
    Liu, Zhuo
    Tan, Jie
    Zhu, Chunrong
    Chen, Minbin
    Zhou, Rengui
    Wane, Lei
    Qian, Jun
    CANCER MANAGEMENT AND RESEARCH, 2020, 12 : 13479 - 13487
  • [3] Retrospective Study on the Efficacy and Safety of Pyrotinib-Based Therapy for HER2-Positive Nonbreast Advanced Solid Tumors
    Wang, Jianzheng
    Zhang, Baiwen
    Cheng, Xiaojiao
    Li, Qingli
    Lv, Huifang
    Nie, Caiyun
    Chen, Beibei
    Xu, Weifeng
    Zhao, Jing
    He, Yunduan
    Tu, Shuiping
    Chen, Xiaobing
    JOURNAL OF ONCOLOGY, 2022, 2022
  • [4] Pyrotinib as a salvage treatment for patients with HER-2 positive advanced lung adenocarcinoma after the progression of afatinib treatment
    Xu, Manyi
    Wang, Yanhua
    Shao, Keda
    Hao, Yue
    Song, Zhengbo
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2024, 26 (12): : 3050 - 3057
  • [5] HER-2/neu overexpression and its effect on survival in solid tumors.
    Tendulkar, K
    Ganti, AK
    Koka, V
    Koch, M
    Potti, A
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 849S - 849S
  • [6] A Retrospective Real-World Study of Pyrotinib in HER-2 Positive Advanced Breast Cancer
    Yang, Zhi
    Fu, Wei-Da
    Gu, Hua-Yan
    Ding, Jia-Ling
    Guo, Gui-Long
    CANCER MANAGEMENT AND RESEARCH, 2025, 17 : 441 - 460
  • [7] A real world study of pyrotinib in patients with HER-2 positive/mutations tumors excluding breast cancer
    Qian, J.
    Yang, H.
    Zhu, C.
    Tan, J.
    Liu, Z.
    Chen, M.
    Zhou, R.
    ANNALS OF ONCOLOGY, 2020, 31 : S934 - S934
  • [8] Efficacy, safety and translational study of pyrotinib combined with albuminbound paclitaxel as firstline treatment of HER-2 positive metastatic breast cancer
    Li, Huihui
    Man, Xiaochu
    Yin, Sha
    Zhou, Dongdong
    Zhang, Baoxuan
    Fang, Shu
    Zheng, Fangchao
    Li, Chao
    Wang, Xinzhao
    Huang, Wei
    Wang, Linlin
    He, Qingqing
    Fu, Hui
    Zhang, Yan
    Liu, Changrui
    Dong, Lin
    Zhao, Xianguang
    Xu, Liang
    Sun, Xiao
    Fan, Bingjie
    Song, Lihua
    Zhou, Zhengbo
    Tan, Qiaorui
    CANCER RESEARCH, 2024, 84 (09)
  • [9] HER2 activity in solid tumors.
    Kujtan, Lara Ann
    Morris, Scott
    Subramanian, Janakiraman
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [10] Pyrotinib combined with SHR6390 in the treatment of refractory advanced HER2 positive gastric cancer or solid tumors: Safety and efficacy results from a phase Id trial.
    Liu, Dan
    Xu, Yingying
    Gong, Jifang
    Yang, Fen
    Shen, Lin
    Li, Huajun
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
12345